Search Results
May 14, 2026, 09:00 ET Young Black and Hispanic Americans Aspire to Homeownership, Entrepreneurship, and Generational Wealth at Higher Rates Than White Peers -- but Face Steeper Structural Barriers
financial marketplace by 2050. Lenders that don't adapt to this reality will be left behind," said Mitria Spotser, president of JBI and a report co-author. The JBI 2050 Survey, conducted by NORC at the University of Chicago, surveyed 5,269 Americans, oversampling white, Black, Hispanic, and Asian
More news about: Julian Bond Institute
Dec 05, 2025, 08:00 ET Jubilant Therapeutics Inc. appoints Daniel J. O'Connor as President and Chief Executive Officer
Optimization), has been validated through successful partnerships. The Company's clinical pipeline consists of a first in class dual CoREST modifier, JBI-802, currently in a Phase I/II clinical trial in multiple tumors and a novel brain-penetrant modulator of PRMT5, currently in Phase I clinical trial. Additional
More news about: Jubilant Therapeutics Inc.
Aug 20, 2025, 17:31 ET HDAC Inhibitors Market Sees Upward Trajectory Across the 7MM During the Forecast Period (2025-2034) Driven by Innovation in Cancer Therapies | DelveInsight
HDAC inhibitors market in the coming years. Some of the key HDAC inhibitors in the pipeline include Abexinostat, Quisinostat, Entinostat, JBI-802, and others.Discover which indication is expected to grab the major HDAC inhibitors market share @
More news about: DelveInsight Business Research, LLP